川芎嗪注射液与丹参滴注液分别治疗急性脑梗死的疗效观察

目的：观察川芎嗪注射液与丹参滴注液分别治疗急性脑梗死的疗效及对患者神经功能的改善情况,进一步探讨两药的作用。方法：选择2012年1—12月收治的急性脑梗死患者129例,以随机抽样法分为治疗组67例和对照组62例,2组患者均根据具体临床情况给予脱水剂降低颅内压、控制血压和血糖等对症治疗,并给予脑保护剂等。在此基础上,治疗组患者给予川芎嗪注射液120 mg加入5%葡萄糖注射液250 ml静脉滴注,1日1次;对照组患者给予丹参滴注液250 ml静脉滴注,1日1次,2组患者均治疗14 d。2组患者治疗前后进行神经功能缺损评分并检测血液流变学指标。结果：治疗14 d后,治疗组总有效率为97.1%（65/67）,对照组总有效率为77.42%（48/62）,2组比较差异有统计学意义（P〈0.05）;且治疗组神经功能缺损评分较对照组显著改善（P〈0.01）,血液流变学指标较对照组也有显著改善（P〈0.05）。结论：川芎嗪注射液对急性脑梗死有较好的治疗作用,安全、有效,且有明显的降血脂作用,临床疗效明显,具有实用和推广价值。

Curative Efficacy of Ligustrazine Hydrochloride Injection vs. Danshen Drip Infusion for Acute Cerebral Infarction

OBJECTIVE ：To evaluate the curative efficacy of Ligustrazine Hydrochloride Injection vs. Danshen drip infusion for acute cerebral infarction and the improvement of neurological function induced by the two drugs so as to further explore the function of the two drugs. METHODS： 129 patients with acute cerebral infarction treated in our hospital during Jan.-Dec. period of 2012 were assigned to either treatment group （67 cases） or control group （62 cases）. Both groups were given symptomatic treatment including dehydrants for lowering intracranial pressure, medications for controlling blood pressure and blood sugar and brain-protective agents; however, the treatment group received add-on Ligustrazine Hydrochloride Injection （120 mg） that added to 5% Glucose Injection （250 ml） iv gtt daily for 14 days and the control group received add-on Danshen drip infusion （250 ml） iv gtt for 14 days. National Institutes of Health Stroke Scale （NIHSS） score and hemorheology in the two groups before and after treatment were compared. RESULTS： After treatment of 14 days, the total effective rates in the treatment group and the control group were 97.1% （65/67） and 77.42% （48/62）, respectively, showing significant differences between the two groups （P 〈 0.05 ） ; the treatment group had significantly better improvement than in the control group in both NIHSS score （P 〈0.01 ） and hemorheology （P 〈0. 05）. CONCLUSION： Ligustrazine Hydrochloride Injection is safe and effective for acute cerebral infarction, and it has remarkable efficacy in lowering blood lipid with satisfactory clinical efficacy and practical and recommended value.